Clinical Trial: the Long-term Retention Rate and Influence Factors of Individualized Treatment of Vedolizumab in Ulcerative Colitis

U.S., March 5 -- ClinicalTrials.gov registry received information related to the study (NCT06856031) titled 'the Long-term Retention Rate and Influence Factors of Individualized Treatment of Vedolizumab in Ulcerative Colitis' on Feb. 10.

Brief Summary: The drug retention rate of vedolizumab for ulcerative colitis decreases with time. This study analyzed the long-term drug retention rate and its influencing factors in patients with moderately to severely active ulcerative colitis treated with vedolizumab.

Study Start Date: Nov. 01, 2020

Study Type: OBSERVATIONAL

Condition: IBD (Inflammatory Bowel Disease)

Intervention: DRUG: Optimized Treatment (OPT)

After induction therapy with intravenous vedolizumab (300 mg) at weeks 0, 2, and 6, ...